2.86
2.51%
+0.07
After Hours:
2.86
Organogenesis Holdings Inc stock is currently priced at $2.86, with a 24-hour trading volume of 778.50K.
It has seen a +2.51% increased in the last 24 hours and a +4.00% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.83 pivot point. If it approaches the $2.88 resistance level, significant changes may occur.
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Organogenesis Holdings Inc (ORGO) Revenue 2024
ORGO reported a revenue (TTM) of $433.14 million for the quarter ending December 31, 2023, a -3.94% decline year-over-year.
Organogenesis Holdings Inc (ORGO) Net Income 2024
ORGO net income (TTM) was $4.95 million for the quarter ending December 31, 2023, a -68.16% decrease year-over-year.
Organogenesis Holdings Inc (ORGO) Cash Flow 2024
ORGO recorded a free cash flow (TTM) of $6.55 million for the quarter ending December 31, 2023, a +172.50% increase year-over-year.
Organogenesis Holdings Inc (ORGO) Earnings per Share 2024
ORGO earnings per share (TTM) was $0.0357 for the quarter ending December 31, 2023, a -70.64% decline year-over-year.
Organogenesis Holdings Inc Stock (ORGO) Latest News
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
GlobeNewswire Inc.
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
GlobeNewswire Inc.
Why Organogenesis Holding Stock Plummeted by 18% Today
The Motley Fool
Organogenesis (ORGO) Q4 2023 Earnings Call Transcript
The Motley Fool
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Zacks Investment Research
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
GlobeNewswire Inc.
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Cap:
|
Volume (24h):